Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT07414836

First seen Feb 21, 2026 · Last updated May 25, 2026 · Updated 14 times

Summary

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 84 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icon Cancer Centre South Brisbane

    RECRUITING

    South Brisbane, Queensland, QLD 4101, Australia

  • Next Oncology San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Northern Beaches Hospital

    RECRUITING

    Frenchs Forest, New South Wales, NSW 2086, Australia

  • Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)

    RECRUITING

    Chongqing, Chongqing Municipality, 400037, China

Conditions

Explore the condition pages connected to this study.